# Efficacy of Roflumilast in the Treatment of Psoriasis

> **NCT04549870** · PHASE2 · COMPLETED · sponsor: **Bispebjerg Hospital** · enrollment: 46 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Roflumilast

## Key facts

- **NCT ID:** NCT04549870
- **Lead sponsor:** Bispebjerg Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-12-12
- **Final completion:** 2022-12-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04549870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04549870, "Efficacy of Roflumilast in the Treatment of Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04549870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*